Cell Therapy Platform Dev With Precigen CEO Dr. Helen Sabzevari
Source: Bioprocess Online
Learn how Precigen is advancing a deep pipeline of immuno-oncology, infectious disease, and autoimmune disorder candidates through the clinic on the back of its UltraCAR-T platform. CEO Dr. Helen Sabzevari describes the promise of the platform to change the CAR T complexity paradigm with an overnight manufacturing process to affect patients in urgent need of timely therapy.
This website uses cookies to ensure you get the best experience on our website. Learn more